Free Trial

Allarity Therapeutics (ALLR) Competitors

Allarity Therapeutics logo
$1.01 -0.07 (-6.48%)
Closing price 07/11/2025 04:00 PM Eastern
Extended Trading
$1.00 -0.01 (-1.19%)
As of 07/11/2025 07:48 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

ALLR vs. ACHL, PDSB, IPA, OTLK, INMB, IRD, NRXP, VTGN, UNCY, and ICCC

Should you be buying Allarity Therapeutics stock or one of its competitors? The main competitors of Allarity Therapeutics include Achilles Therapeutics (ACHL), PDS Biotechnology (PDSB), ImmunoPrecise Antibodies (IPA), Oncobiologics (OTLK), INmune Bio (INMB), Opus Genetics (IRD), NRx Pharmaceuticals (NRXP), VistaGen Therapeutics (VTGN), Unicycive Therapeutics (UNCY), and ImmuCell (ICCC). These companies are all part of the "pharmaceutical products" industry.

Allarity Therapeutics vs. Its Competitors

Achilles Therapeutics (NASDAQ:ACHL) and Allarity Therapeutics (NASDAQ:ALLR) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their risk, institutional ownership, valuation, media sentiment, dividends, analyst recommendations, profitability and earnings.

In the previous week, Allarity Therapeutics had 5 more articles in the media than Achilles Therapeutics. MarketBeat recorded 5 mentions for Allarity Therapeutics and 0 mentions for Achilles Therapeutics. Allarity Therapeutics' average media sentiment score of 0.37 beat Achilles Therapeutics' score of 0.00 indicating that Allarity Therapeutics is being referred to more favorably in the news media.

Company Overall Sentiment
Achilles Therapeutics Neutral
Allarity Therapeutics Neutral

Achilles Therapeutics has a beta of 1.25, meaning that its stock price is 25% more volatile than the S&P 500. Comparatively, Allarity Therapeutics has a beta of 0.04, meaning that its stock price is 96% less volatile than the S&P 500.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Achilles TherapeuticsN/AN/A-$69.67M-$1.65-0.90
Allarity TherapeuticsN/AN/A-$24.51MN/AN/A

Achilles Therapeutics' return on equity of -54.45% beat Allarity Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Achilles TherapeuticsN/A -54.45% -47.68%
Allarity Therapeutics N/A -147.94%-90.33%

56.4% of Achilles Therapeutics shares are held by institutional investors. Comparatively, 11.5% of Allarity Therapeutics shares are held by institutional investors. 5.4% of Achilles Therapeutics shares are held by insiders. Comparatively, 0.1% of Allarity Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

Achilles Therapeutics beats Allarity Therapeutics on 5 of the 8 factors compared between the two stocks.

Get Allarity Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for ALLR and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ALLR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ALLR vs. The Competition

MetricAllarity TherapeuticsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$15.23M$2.94B$5.56B$9.11B
Dividend YieldN/A2.42%5.06%4.01%
P/E RatioN/A20.8528.2620.26
Price / SalesN/A303.05437.10166.10
Price / CashN/A42.1137.1257.67
Price / Book0.627.638.045.49
Net Income-$24.51M-$55.05M$3.19B$250.45M
7 Day Performance0.40%8.43%3.62%4.79%
1 Month Performance25.73%8.14%5.98%9.59%
1 Year Performance-82.82%1.62%29.39%16.41%

Allarity Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ALLR
Allarity Therapeutics
0.6623 of 5 stars
$1.01
-6.5%
N/A-82.8%$15.23MN/A0.0010Gap Down
ACHL
Achilles Therapeutics
N/A$1.48
flat
N/AN/A$60.83MN/A-0.90250
PDSB
PDS Biotechnology
1.307 of 5 stars
$1.22
-8.3%
$9.00
+637.7%
-69.7%$60.79MN/A-1.3020News Coverage
IPA
ImmunoPrecise Antibodies
3.0875 of 5 stars
$1.63
+24.4%
$4.00
+145.4%
+49.5%$59.95M$18.16M-1.4180Positive News
Upcoming Earnings
Gap Down
OTLK
Oncobiologics
2.3694 of 5 stars
$1.86
+4.5%
$9.60
+416.1%
-76.4%$59.75MN/A-2.0420Positive News
INMB
INmune Bio
2.3292 of 5 stars
$2.30
-9.1%
$18.40
+700.0%
-75.0%$59.67M$10K-1.1910Positive News
High Trading Volume
IRD
Opus Genetics
1.6529 of 5 stars
$0.99
-0.8%
$7.33
+639.2%
N/A$59.66M$10.99M-0.4714News Coverage
Analyst Upgrade
NRXP
NRx Pharmaceuticals
2.8018 of 5 stars
$3.37
-0.3%
$28.50
+745.7%
+29.4%$58.44MN/A-1.682Positive News
VTGN
VistaGen Therapeutics
0.934 of 5 stars
$2.21
+10.5%
N/A-38.0%$58.31M$490K-1.3340Positive News
High Trading Volume
UNCY
Unicycive Therapeutics
3.0084 of 5 stars
$4.69
+2.0%
$60.00
+1,179.3%
+1.2%$58.15MN/A-0.929High Trading Volume
ICCC
ImmuCell
0.2434 of 5 stars
$6.53
+2.2%
N/A+50.7%$57.79M$26.49M-93.2770News Coverage

Related Companies and Tools


This page (NASDAQ:ALLR) was last updated on 7/13/2025 by MarketBeat.com Staff
From Our Partners